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CD45 is a family of transmembrane glycoproteins that
function as protein tyrosine phosphatases. All isoforms
exhibit common CD45 epitopes, whereas the restricted
CD45 epitopes (RA, RB, and RO) are each limited to
one or more isoforms. In prior studies, we showed that
human Langerhans cells in normal epidermis express a
novel CD45 phenotype. They express common CD45
epitopes but are characteristically RA–RB–RO–. This
suggests that Langerhans cells can express a novel form
of CD45. In order to clarify this issue further, mRNA
extracted from enriched Langerhans cell preparations was
reverse transcribed into cDNA. The 59 portion of CD45
cDNA was then amplified using polymerase chain
reaction primers complementary to exon 2 and exons
9–10, which flank the CD45 variable exon region (exons
4–6). Cloning and sequencing of the dominant 441 bp
polymerase chain reaction product revealed the following
exon configuration for the 59 translated region of Langer-
hans cells CD45: exon 3/7/8/9/10. This is the same exon
configuration associated with the 180 kd CD45 isoform
expressed by memory T cells and monocytes/macro-
The human CD45 antigen consists of a family of heavilyglycosylated transmembrane proteins, one or more ofwhich are expressed by all bone marrow-derived cellsof leukocytic lineage, including Langerhans cells (Woodet al, 1985a; Cobbold et al, 1987; McMichael, 1987a,
b). CD45 molecules function as protein tyrosine phosphatases (PTPases)
involved in the positive regulation of T cell and B cell antigen receptor
signaling via activation of Src family kinases (Cahir McFarland et al,
1997; Ulyanova et al, 1997; Wallace et al, 1997). Through this and
other mechanisms, CD45 has been implicated in a variety of leukocyte
functions including thymocyte selection and maturation, cytotoxicity,
apoptosis, expression of interleukin-2 receptor and L-selectin, sup-
pressor inducer function by CD41 T cells, immunoglobulin production,
T cell trafficking, and neutrophil chemotaxis (Shen et al, 1985; Saga
et al, 1986; Cobbold, 1987; McMichael, 1987a, b; Koretsky et al, 1991;
Stover et al, 1991; Alexander et al, 1992; Streuli et al, 1992; Conroy
et al, 1996; Kozieradzki et al, 1997; Latinis, 1997; Wang et al, 1997;
Wroblewski, 1997). Furthermore, it has been proposed that the
contact inhibition of cell division and motility may be mediated
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phages; however, these cell types are ROF whereas
normal Langerhans cells are RO–. The RO epitope is
known to be an oligosaccharide with a terminal sialic
acid moiety. Therefore, we determined the expression of
a related epitope, OPD4, by Langerhans cells. This is
another terminal sialic acid moiety expressed by the
180 kd CD45 isoform of memory T cells but not by
monocytes/macrophages. Langerhans cells were OPD4–.
Our data suggest that memory T cells, monocytes/
macrophages, and Langerhans cells all express a common
CD45 transcript lacking exons 4–6; however, this tran-
script appears to undergo lineage-specific, post-transla-
tional glycosylation to create three distinct CD45
glycoproteins: ROFOPD4F, ROFOPD4–, and RO–
OPD4–, which are expressed typically by memory T
cells, monocytes/macrophages, and Langerhans cells,
respectively. Because these epitopes are located extracel-
lularly, they are postulated to allow differential responses
to extracellular stimuli by creating differential ligand
specificity. Key words: protein tyrosine phosphatase/RT/PCR.
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by transmembrane molecules with CD45-type intracellular domains
(Streuli et al, 1989). In this context, CD45 has been associated with
the cytoskeletal component fodrin (Suchard, 1987). The B cell antigen,
CD22, has been identified as a ligand for CD45RO, providing
additional evidence that CD45 molecules are involved in cell–cell
interactions (Stamenkovic et al, 1991).
There are multiple isoforms of human CD45, all encoded by a
single gene that is situated on the long arm of chromosome 1 in the
q31–32 region (Ralph et al, 1987; Streuli et al, 1987, 1988; Hall et al,
1988; Streuli and Saito, 1989; Ratech et al, 1997). There are 33 exons
that encode the entire cDNA sequence of the largest CD45 isoform,
including 59 and 39 untranslated regions. The human CD45 isoforms
can be segregated into four glycoprotein bands (180 kd, 190 kd, 200–
210 kd, and 220 kd) by immunoprecipitation and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. The exon organization of
these isoforms determines their molecular weight and is associated with
specific patterns of CD45 epitope expression (Table I). This occurs
by alternative splicing of CD45 mRNA involving exons 4, 5, and 6
(the three known variable exons in humans).
In 1984, we reported that human and rodent Langerhans cells
express CD45 based on their reactivity with anti-CD45 monoclonal
antibodies at both the light microscopic and the ultrastructural levels
(Wood et al, 1984, 1985b). Subsequently, we used two-color epitope
mapping to show that Langerhans cells in normal human epidermis
express a unique CD45 phenotype: CD451RA–RB–RO– (Wood et al,
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Table I. Molecular and antigenic characteristics of six known human CD45 isoformsa
Exons in mRNA Protein molecular weight CD45 common CD45RA CD45RB CD45RC CD45RO
1–2–3–4–5–6–7–etc. 220 kd 1 1 1 1 –
1–2–3–4–5–7–etc. 205 kd 1 1 1 – –
1–2–3–5–6–7–etc. 200 kd 1 – 1 1 –
1–2–3–4–7–etc. 190 kd 1 1 – – –
1–2–3–5–7–etc. 190 kd 1 – 1 – –
1–2–3–7–etc. 180 kd 1 – – – 1
aBased on the data of Streuli et al (1987, 1988) and Ratech et al (1997). Potential isoforms encoded by transcripts containing only exons 4 and 6, or exon 6 alone, in their variable
regions have not been identified in humans. Multiple antibodies specific for CD45 common, RA, RB, and RO epitopes have been described. Antibody YTH80.103 has been reported
to have putative specificity for CD45RC (exon 6-encoded epitope) (Schwinzer et al, 1995).
1991). This suggested that they express a novel CD45 isoform because
all known isoforms contain at least one restricted epitope (RA, RB,
or RO) (Table I). Two major possibilities existed. First, Langerhans
cell CD45 might have a novel exon configuration and primary protein
structure. This novel structure would then result in a novel pattern of
CD45R epitope expression because most CD45R epitopes are known
to be, or to be closely associated with, O-linked oligosaccharides
whose presence correlates with the presence of specific CD45 exons:
CD45RA (exon 4), CD45RB (exon 5), CD45RO (exon 3/7 junction)
(Barclay et al, 1987; Streuli et al, 1988; Pulido, 1989; Poppema et al,
1991; Wood, 1991; Knowles et al, 1992; Saunders et al, 1995). An
alternative possibility was that Langerhans cells might express one or
more of the known CD45 transcripts, but that this message might
undergo a novel form of post-translational processing so that it would
exhibit a different pattern of O-linked oligosaccharides and therefore
a novel pattern of CD45 epitopes. For example, this type of differential,
cell-specific glycosylation is known to occur with the CD43 molecule
(Peacocke, 1992).
MATERIALS AND METHODS
Immunoperoxidase analysis Immunostaining of cryostat sections of skin,
epidermal strips, and cytocentrifuge preparations of enriched Langerhans cells
were performed as described previously (Wood, 1982) using a three stage
method consisting of (i) murine monoclonal antibody, (ii) biotin conjugated
F(ab9)2 fragments of goat anti-mouse IgG, and (iii) avidin-horseradish peroxidase.
The chromagen was 3,3-diaminobezidine. Controls included irrelevant primary
antibodies of similar isotype and staining with various stages deleted.
Monoclonal antibodies Several monoclonal antibodies were used for
immunostaining of cryostat sections of intact skin and epidermal strips, cyto-
centrifuge preps, and western blots. These included NA1/34 (CD1a) (Dako,
Carpinteria, CA); Leu4 (CD3), LeuM3 (CD14), Leu14 (CD22) (all from
Becton Dickinson, San Jose, CA); CD45 common antibodies 2D1 (Dako),
T29/33 (Boehringer Mannheim, Indianapolis, IN), and BMAC3 (Rosemarie
Dalchau, Sussex, U.K.); CD45RA antibody Leu18 (Becton Dickinson);
CD45RB antibody PD7/26 (David Mason, Oxford, U.K.); CD45RO antibody
UCHL1 and OPD4 (both from Dako).
Langerhans cell enrichment from whole skin A fresh skin specimen
(ù4 3 6 cm) was placed into saline or 13phosphate-buffered saline pH 7.4 at
4°C (on ice) prior to being cut into 0.5 3 2 cm strips. Strips were incubated
dermal side down in 1% Dispase (Boehringer Mannheim) in Tyrode’s salts
solution (Sigma) at 4°C overnight. Following incubation at 37°C for half an
hour, the epidermis was peeled away and rinsed in phosphate-buffered saline.
Some of these epidermal strips were then processed directly for RNA extraction.
They showed disruption through the basal layer with an intact suprabasilar
region containing a normal complement of dendritic CD1a1 Langerhans cells.
No leukocytes or macrophages were detectable within the strips using anti-T cell
(CD3), anti-B-cell (CD22), or anti-macrophage (CD14) monoclonal antibodies.
Some epidermal strips were floated dermal side down in 5 ml of 0.15%
trypsin (bovine, Sigma) in phosphate-buffered saline and incubated at 37°C.
After an initial 10 min period, the strips were agitated every 5 min for at least
30 min, not exceeding 1 h total incubation time. DNAse (Promega, Madison,
WI) was added to a concentration of 3 units per ml, and the suspension was
mixed 10 times with a pipet. The stratum corneum was aseptically removed,
and an equal volume (5 ml) of complete RPMI was used to wash the cell
suspension into a 15 ml tube. Cells were pelleted in an IEC HN-SII centrifuge
for 8 min at 1100 rpm. The supernatant was discarded, and cells resuspended
in 5 ml of complete RPMI 1640. The cell suspension was filtered through a
100 µm sieve, then passed through a 26 gauge needle, and filtered through a
Figure 1. Schematic diagram of overlapping PCR primers used to
determine the exon configuration of Langerhans cell CD45 cDNA.
38 µm sieve to obtain a single cell suspension. A sample was removed to check
cell count and viability. Desired cell concentration was 5 million to 20 million
cells per ml.
Magnetic beads (Dynabeads M-450, Dynal, Lake Success, NY) were used in
conjunction with unconjugated OKT6 (CD1a) monoclonal antibody (Ortho)
to isolate the Langerhans cells. A modification of the direct method was used.
The beads were washed with cold complete RPMI 1640 instead of phosphate-
buffered saline/bovine serum albumin, both before and after addition, and
incubation with, antibody (90 min at 4°C). The epidermal cell suspension was
added to the washed, antibody-coated beads, and incubated for 90 min at 4°C
with gentle agitation. This was followed by three washes with cold complete
RPMI and final resuspension of beads/target cells (Langerhans cells) in cold
complete RPMI. A sample was removed for cell counting, and appropriate
numbers of Langerhans cells were transferred to Eppendorf tubes. The enriched
Langerhans cells were 80%–90% pure with 10%–20% residual keratinocytes and
no leukocytes or macrophages detectable by immunostaining of cytocentrifuge
preparations with anti-T cell (CD3), anti-B cell (CD22), or anti-macrophage
(CD14) monoclonal antibodies. The enriched Langerhans cells were pelleted,
and supernatants decanted. The cell pellets were used for immediate RNA
extraction or snap-frozen for future RNA extraction. Beads were not removed
from the cells, but did not appear to interfere with RNA extraction.
CD45 oligonucleotide primers and internal probe The exon configura-
tion of the entire extracellular domain of Langerhans cell CD45 was sequenced
following reversetranscriptase/polymerase chain reaction (RT/PCR) amplifica-
tion of the overlapping regions illustrated in Fig 1. The oligonucleotide primer
pairs used to amplify these segments are listed in Table II.
RT/PCR Total RNA from isolated Langerhans cells and epidermal strips
was recovered utilizing the acid guanidinium thiocyanate extraction method of
Chomoczynski and Sacchi (1987) as described previously by us (Longley et al,
1991). Fresh or snap-frozen cells (104–106) were homogenized. DNA and
proteins were removed with a salt/phenol/chloroform extraction, leaving the
RNA in the aqueous phase. The RNA was precipitated with two volumes of
100% isopropyl alcohol at –20°C for a minimum of 1 h. The precipitate was
pelleted by centrifugation and washed twice with 80% ethyl alcohol to remove
any contaminating guanidinium and other salts. The pellet was vacuum dried
and resuspended in sterile deionized water. The limited amount of RNA
recovered was used directly for reverse transcription and amplification.
First-strand cDNA synthesis was carried out using Superscript RNAse H–
Reverse Transcriptase (Gibco BRL, Gaithersburg, MD) or Amv reverse
transcriptase (Promega) and an appropriate downstream primer. Second-strand
cDNA synthesis and subsequent amplification were accomplished using Ampli-
Taq DNA polymerase (Perkin Elmer-Cetus, Branchburg, NJ) and appropriate
primer pairs. Typically, amplification was performed for 30 cycles in a thermal
cycler (denaturation 3 1 min at 94°C, annealing 3 1 min at 50–65°C, and
extension at 60–72°C) at the highest possible temperatures within these ranges
in order to minimize amplification of nontarget sequences. The RT/PCR
product was screened on a 1% agarose gel and compared with molecular weight
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Table II. CD45 oligonucleotide primer pairs and internal probea
W2: (–14)TTCCAGATATGACCATGTATTTGTGGC(13) uptream
W9/10: (883)ACTTTTCAACCCCTGGTGGCACATCTAA(910) downstream
W9: (773)GTGGAAACAATACTTGCACAAACAATGAGG(802) upstream
W11/12: (1162)AAATAATCTGAGGCTCTCCTGGACTCCC(1189) downstream
W10/11: (1007)TTACCTACAGATTTCAGTGTGG(1028) upstream
W14: (1587)CTTATGCGACTCATTTCTAACC(1599) downstream
W13: (1387)GCAAAAGTGCAACGTAATGGAA(1408) upstream
W17: (1980)CCTTTATAGGAAACTTGCTGAACACC(2005) downstream
W7: (612)GAGCCCTTCTGGAAGCGCTGTCATTTCAACCACAA(646) internal probe
aSequence numbering according to Streuli et al (1987).
markers for determination of size and approximate quantity of amplified cDNA.
The identity of the polymerase chain reaction (PCR) products was confirmed
by Southern blot analysis (Sambrook et al, 1989) using a nested oligonucleotide
DNA probe complementary to a portion of CD45 exon 7 (Table II).
DNA sequencing The PCR products obtained using primer pairs W2, W9/
10 and W13, W17 were ligated into the pCRII vector (Invitrogen, San Diego,
CA) based on overhanging A-T complementarity. The Escherichia coli strain
INVαF (Invitrogen) was transformed with the vector and spread on LB/
ampicillin plates containing X-GAl. Positive colonies were grown overnight in
Luria broth containg ampicillin. Plasmid DNA was extracted and purified using
Magic Maxipreps (Promega). Insertion of the target DNA was confirmed by
Eco RI digestion. Target DNA was sequenced using standard autoradiographic
methods (Sambrook, 1989) and using the AutoRead Sequencing Kit (Pharmacia
LKB) that utilizes the Sanger dideoxy sequencing method (Sambrook, 1989)
with fluoroscein labeled primers. Four-color sequence data were generated by
the Automated Laser Fluorescent (ALF) DNA Sequencer (Pharmacia LKB),
and analyzed concurrently by computer.
The exon 2–9/10 and 13–17 regions amplified well using enriched Langerhans
cells preparations; however, the region spanning exons 10–13 was more difficult
to amplify despite the use of several alternative primers flanking this region
(sequences not shown). We suspected that secondary structure might be
interfering with efficient RT/PCR. Therefore, we modified our methods for
this region. RNA was extracted from epidermal strips and amplified using W9,
W11/12 and W10/11, W14 primer pairs. Products from multiple RT/PCR
reactions were pooled, concentrated, digested with NlaIII to generate compatible
ends with SphI-cut pUC 18 and pUC 19 vectors, and electrophoresed on
Nusieve GTG agarose gels. Fragments of appropriate size were isolated, ligated
into the vectors, cloned, and sequenced as described above.
RESULTS
The major Langerhans cell CD45 transcript lacks variable
exons RNA extracted from epidermal strips and freshly enriched
normal epidermal Langerhans cells was reverse transcribed into cDNA.
We obtained better yields using a downstream primer rather than
random hexamers. Because all known variability in CD45 primary
structure originates from the presence or absence of the so-called
variable exons (4, 5, and 6) (Table I), we focused our attention on
the 59 translated region of CD45 (exons 3–10). The 59 portion of
CD45 cDNA was PCR amplified using primers complimentary to
exon 2 and exons 9–10 that flank the CD45 variable exon region
(exons 4, 5, and 6) (Fig 2). A dominant 441 bp PCR product was
amplified from both epidermal strips and enriched Langerhans cells
along with small amounts of a larger 582 bp band. In contrast, similar
amplification of peripheral blood mononuclear leukocytes produced
the 441 bp band as well as larger amounts of multiple heavier bands.
This was not unexpected for blood leukocytes that are known to
produce multiple CD45 isoforms (Wood, 1991). It indicates that the
dominance of the 441 bp product in Langerhans cells was not simply
due to its shorter length. The similar findings from both epidermal
strips and enriched Langerhans cells indicate that the Langerhans cells
isolation process we employed did not significantly alter their expression
of CD45 transcripts. The CD45 nature of these PCR products was
confirmed by Southern blot analysis using a nested, exon 7-specific
oligonucleotide probe.
The Langerhans cell PCR products were ligated into the pCRII
vector (Invitrogen) based on overhanging A-T hybridization and
cloned in E. coli. All 12 colonies tested contained the 441 bp insert
except two that contained the 582 bp insert. These were sequenced
by the dideoxy method using conventional sequencing gels and
Figure 2. The dominant Langerhans cell CD45 RT/PCR product is
441 bp using primers W2 and W9/10. Mingel of RT/PCR products
amplified using primers complementary to exon 2 and exon 9/10 that flank
the CD45 cDNA variable region (exons 4–6). Langerhans cells (lanes 4 and 5)
exhibit a dominant 441 bp band (arrow) whereas peripheral blood mononuclear
leukocytes (lanes 2 and 3) exhibit multiple bands. Each of these lanes represents
100,000 cells except lane 4 (240,000 cells). Lane 1 is a φX174/Hae III digest.
Lane 6 is the carryover negative control.
autoradiography (see Fig 3) as well as a computerized, automated
nucleotide sequencer (Pharmacia) that utilizes a nonradioactive
fluorochrome labeling system. Results were similar and revealed the
following exon figuration for the 59 translated region of the 441 bp
product: exon 3/7/8/9/10. This confirmed our previous preliminary
findings.1
All known isoform diversity within the human CD45 protein family
arises from alternate splicing involving exons 4, 5, and 6 (Wood,
1991). Therefore, the remaining unsequenced extracellular domain of
Langerhans cell CD45 was highly likely to have the same exon
configuration as all other known isoforms. Nevertheless, in order to
confirm this structure for Langerhans cell CD45, we sequenced the
remainder of the extracellular domain extending well into exon 17,
which encodes the first intracytoplasmic region of CD45 adjacent
to the exon 16 transmembrane domain. Results showed an exon
configuration identical to all other known isoforms of CD45: 10/11/
12/13/14/15/16/17.
Normal epidermal Langerhans cells lack CD45R epitopes In
aggregate, these sequencing studies showed that the major form of
CD45 expressed by normal epidermal Langerhans cells has the same
exon configuration spanning its entire extracellular domain (3/7/8/9/
10/11/12/13/14/15/16/17) as the 180 kd CD45 isoform expressed
by memory T cells and, more weakly, by monocytes. These cells,
however, are CD45RO1 whereas Langerhans cells in normal epidermis
are generally CD45RO– (Wood, 1991). The CD45RO epitope is
known to be an oligosaccharide with a terminal sialic acid moiety
(Pulido, 1989; Poppema, 1991). Therefore, we determined the expres-
sion of a related epitope, OPD4, by Langerhans cells. This epitope
also involves a terminal sialic acid moiety expressed by the 180 kd
1Wood GS, Crooks CF, Szwjebka P, Schwandt A: Human Langerhans cell
CD45. J Invest Dermatol 100:560, 1993 (abstr.)
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CD45 isoform of memory T cells, but not by monocytes (Pulido,
1989; Yoshido et al, 1989; Poppema, 1991). Fourteen tissue specimens
were analyzed, including four normal skin (two breast, two nose), one
reactive tonsil, two chronic spongiotic dermatitis, five mycosis fungoides
(four patch/plaque, one tumor), one cutaneous lymphoid hyperplasia,
and one cutaneous sinus histiocytosis (Rosai-Dorfman disease). In
all samples, CD1a1 Langerhans cells were OPD4–. This included
Langerhans cells in epidermis, cutaneous adnexal epithelium, and tonsil
epithelium. In contrast, CD31 T cells in these specimens were OPD41
as expected. Representative findings are shown in Fig 4.
The minor Langerhans cell CD45 transcript contains variable
exon 5 The larger 582 bp cloned PCR product was subjected to
similar sequence analysis and exhibited the following exon configura-
tion: 3/5/7/8/9/10. This was reminiscent of the 190 kd CD45 isoform
expressed by certain leukocytes and associated with a CD45RB1
phenotype in these cells.
DISCUSSION
In this study, we analyzed the structure of the 59 translated regions of
normal epidermal Langerhans cell CD45 transcripts. We identified a
Figure 3. Sequencing shows that Langerhans cell CD45 contains the
exon 3/7 junction. Nucleotide sequence of the Langerhans cells 441 bp RT/
PCR product. Conventional sequencing gel autoradiogram illustrates the exon
3–exon 7 junction (arrow) with deletion of all intervening CD45 variable exons
(exons 4–6).
Figure 4. Langerhans cells in situ lack expression of both UCHL1 and OPD4 epitopes. Immunoperoxidase stained frozen sections of skin show that
epidermal CD1a1 Langerhans cells (A) express CD45 common epitope 2D1 (B) but lack expression of the CD45RO-related epitopes UCHL1 (C) and OPD4
(D). Dermal histiocytes and lymphocytes reactive with 2D1 (B) and UCHL1 (C) are also present, as well as a single dermal lymphocyte stained by OPD4 (D).
Methylene blue counterstain; scale bar: 30 µm.
major 59 transcript sequence with an exon 3/7/8/9/10 configuration
and a minor 59 transcript sequence with an 3/5/7/8/9/10 configuration.
These results are consistent with our prior finding that Langerhans
cells are CD45RA– (Wood, 1991) because expression of the CD45RA
epitope is dependent upon synthesis of CD45 transcripts containing
exon 4 (Ralph, 1987; Streuli et al, 1987, 1988, 1989; Hall, 1988). No
RT/PCR products shorter than 441 bp were identified. This agrees
with similar studies of thymocytes and T cell neoplasms, and indicates
that variable splicing involving exons 7 and 8, which has been reported
in mice, does not occur in these human cells (Ratech, 1997).
The same exon configurations that we identified in Langerhans cell
CD45 transcripts are associated with the 180 kd and 190 kd CD45
isoforms, respectively, that are expressed by various other leukocyte
subsets (Ralph, 1987; Hall, 1988; Streuli et al, 1987, 1988, 1989).
Among these other leukocytes, expression of the 180 kd isoform is
associated with expression of the CD45RO epitope and expression of
the 190 kd isoform is associated with expression of the CD45RB
epitope; however, prior studies showed that Langerhans cells in normal
epidermis are typically CD45RB–RO– (Wood, 1991). The CD45RO
epitope is expressed by memory T cells and monocytes and is known
to be an oligosaccharide involving a terminal sialic acid moiety (Pulido,
1989; Poppema, 1991). Therefore, we studied Langerhans cells for
expression of a related epitope, OPD4. The OPD4 epitope also
involves a terminal sialic acid moiety and is expressed by the 180 kd
CD45 isoform of memory T cells but is not expressed by monocytes
(Pulido, 1989; Yoshido, 1989; Poppema, 1991; Macardle et al, 1995).
Langerhans cells were OPD4–; however, most intraepidermal and
intradermal T cells were strongly OPD41.
Therefore, our data suggest that normal memory T cells, monocytes,
and Langerhans cells all express a shared CD45 transcript lacking exons
4, 5, and 6; however, this transcript appears to undergo lineage-
specific post-translational glycosylation to create three distinct CD45
glycoproteins: CD45RO1 OPD41, CD45RO1 OPD4–, and
CD45RO– OPD4– that are expressed by memory T cells, monocytes,
and Langerhans cells, respectively. Because these epitopes are located
extracellularly, we postulate that they allow differential responses to
extracellular stimuli by creating differential ligand specificity.
These findings are important because they indicate a previously
unrecognized mechanism for CD45 molecular diversity. A similar
system of cell type-specific and developmental stage-specific variation
in glycosylation has been described for CD43, another membrane-
associated, glycoprotein widely expressed by leukocytes (Peacocke,
1992). The potential for structural diversification inherent in the
differential glycosylation of proteins can be appreciated by recalling
that the linking of two amino acids can create only two unique
structures (A-B or B-A), whereas the linking of two hexose sugars can
create 16 unique structures. Because memory T cells retain strong
expression of CD45RO and OPD4 epitopes when they infiltrate the
epidermis, the intraepidermal microenvironment, per se, cannot be
presumed to exert a downregulatory effect on, or masking, CD45RO
and OPD4 expression by leukocytes. Their absence from Langerhans
cells appears to be lineage specific as opposed to microenvironment
specific. CD43, CD44, and CD45 molecular weight in EL-4 thymoma
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cells can be increased by transfection with core 2 β 1→6 N-
acetylglucosaminyltransferase, which increases the branching of O-
linked glycans (Baran et al, 1997). It is possible that lineage-specific,
activation-specific, or maturation stage-specific differences in the activ-
ity of such enzymes involved in the O-glycan biosynthetic pathway
might help explain the unique structure of Langerhans cell CD45 in
normal human epidermis.
Support for this concept comes from a prior study (Bieber et al,
1995) that showed that freshly isolated normal epidermal Langerhans
cells could alter their CD45R expression in vitro over time or in
response to cytokines. The authors postulated that their isolation
and culture of Langerhans cells induced activation events promoting
Langerhans cell differentiation or maturation accompanied by a shift
in CD45R phenotype. These findings are consistent with our earlier
observation that peripheral blood dendritic cells differ from epidermal
Langerhans cells in their CD45 phenotype. Like epidermal Langerhans
cells, they express high levels of CD45 common epitopes; unlike
epidermal Langerhans cells, they express low levels of CD45RO and
moderate levels of CD45RB (Wood, 1991).
In concurrence with our current and past findings (Wood, 1991)
concerning the CD45 phenotype of normal Langerhans cells in intact
epidermis, Bieber et al (1995) also found that freshly isolated Langerhans
cells expressed CD45 common epitopes but lacked CD45RA and
CD45RB. It is possible that alterations induced by their Langerhans
cells enrichment procedure (Bieber et al, 1989) might explain why
they found that a majority, but not all, of their freshly isolated
Langerhans cells expressed some CD45RO, whereas we found that
Langerhans cells in intact normal epidermis typically lack CD45RO.
Differential sensitivity of the detection methods used (three-stage
immunoperoxidase staining versus two-stage fluorescence-activated cell
sorter analysis) is unlikely to account for this discrepancy because we
previously observed a good correlation between these two methods
when applied to the immunophenotyping of dendritic cells (Wood,
1991, 1992; Freudenthal, 1993). In addition, Langerhans cells in intact
epidermis also lacked CD45RO using sensitive two-color in situ
immunofluorescence techniques (Wood, 1991). In aggregate, our data
indicate that Langerhans cells in intact epidermis express little or no
CD45RO. Nevertheless, even if they expressed very low level
CD45RO in situ, it would have to be far less than their expression
of CD45 common antigens. At the very least, this implies novel
hypoglycosylation of Langerhans cell CD45 framework proteins relative
to other cells, such as T cells, that strongly express both CD45 common
and CD45RO epitopes whether assessed by in situ immunoperoxidase,
in situ immunofluorescence, or fluorescence-activated cell sorter
analysis. Unfortunately, Bieber et al presented no data concerning the
absolute or relative intensity of the CD45RO expression that they
detected in a subset of their isolated Langerhans cells.
The minor CD45 transcript that we detected in Langerhans cells
had an exon 3/5/7/8/9/10 configuration identical to the 190 kd
CD45 isoform expressed by other leukocytes and usually associated
with expression of the CD45RB epitope (Ralph et al, 1987; Streuli
et al, 1987, 1988, 1989; Hall, 1988). Because intact epidermal Langer-
hans cells and freshly isolated Langerhans cells are typically CD45RB–
(Wood, 1991; Bieber, 1995), and the CD45RB antigen is known to
be another O-linked oligosaccharide with a terminal sialic acid moiety
(Pulido, 1989), this may represent another example of lineage-specific
differences in glycosylation. Alternatively, because this product was
relatively rare, it might represent very low-level expression of the
conventional CD45RB1 isoform containing exon 5 but lacking exons
4 and 6. In this case, its antigen density would be too low to generally
detect using conventional immunophenotyping methods.
In addition to their demonstrated value in analyzing the structure
of CD45 isoforms, the techniques employed in this study should be
equally useful for investigating the structure of other molecules
expressed by Langerhans cells or other rare cell types. Once the cells
of interest are enriched and depleted of any relevant contaminating
cell types, sequence analysis of RT/PCR products can be used to
determine the structure of gene transcripts and thereby deduce the
primary structure of corresponding protein products. Provided that an
appropriate panel of antibodies is available, prosthetic groups attached
to these proteins can be further characterized by epitope mapping
studies performed on tissue sections or cell suspensions. Together, these
methods can define a wide variety of protein structural features. They
are especially useful for studying proteins expressed by rare cells that
are difficult to harvest in numbers adequate for analysis of mRNA by
northern blotting or analysis of proteins by western blotting or
immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel
electrophoresis.
Supported by NIH grant AR40844 and Merit Review funding from the Department
of Veterans Affairs.
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